[Reactivity and communication of Health Authorities toward health professionals: a public health priority].
OBJECTIVE
evaluate the impact of Health Authorities' communication on medical practices through 2 examples: celecoxib, taking into account the recent countra indication related to cardio vascular risks; pergolide, taking into account the risk of cardiac valvulopathy.


METHODS
Use of the Pays de Loire Health Insurance Administration data base to monitor the number of cardio vascular patients at risk who receive celecoxib, and cardiac surveillance of pergolide exposed patients.


RESULTS
Communication from Health Authorities resulted in a major decrease (71.9%) of the number of risking patients who take celecoxib, and a significant 14% decrease of pergolide treated patients needing cardiac monitoring


CONCLUSIONS
Unlike the information related to pergolide, the information related to celecoxib was fully taken into account. The difference seems to come from the fact that one was widely relayed by medias, not the other.
Victorri-Vigneau
Caroline
C
Service de Pharmacologie Clinique, CHU de Nantes, Institut de Biologie, Nantes, France. caroline.vigneau@chu-nantes.fr
Marais
Marie
M
Veyrac
Gwenaëlle
G
Chaslerie
Anicet
A
Pivette
Jacques
J
Jolliet
Pascale
P
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004363:Drug Utilization; D005602:France; D006801:Humans; D033183:Interdisciplinary Communication; D010479:Pergolide / Q000009:adverse effects / Q000627:therapeutic use; D011634:Public Health / Q000706:statistics & numerical data*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use
D000978:Antiparkinson Agents; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D010479:Pergolide; D000068579:Celecoxib